Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by IAMA Therapeutics

News headline image
IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe Forum
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics to Present at Upcoming BIO International Convention
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Announces Addition of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to Scientific Advisory Board
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics to Present Data on Its Epilepsy Program at American Academy of Neurology Annual Meeting (2023)
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Announces Formation of Scientific Advisory Board
From IAMA Therapeutics
Via Business Wire
News headline image
IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
From IAMA Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.